Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy: a Multicenter Randomized Double-blind Placebo-controlled Phase III Trial.

NCT01707966 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT01707966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01707966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy: a Multicenter Randomized Double-blind Placebo-controlled Phase III Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2012
Completion date
July 31, 2016
Enrollment
47 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer